What is Onivyde and what does it treat?
Onivyde is a chemotherapy drug used to treat pancreatic cancer. It is an encapsulated form of irinotecan, a topoisomerase I inhibitor, that is specifically designed to accumulate in tumor tissue [1]. Onivyde is approved for patients with metastatic pancreatic adenocarcinoma who have been previously treated with gemcitabine-based chemotherapy [2].
What are the alternatives to Onivyde for pancreatic cancer?
For patients with metastatic pancreatic adenocarcinoma who have progressed on gemcitabine-based chemotherapy, Onivyde is typically used in combination with other drugs, specifically fluorouracil and leucovorin. This combination, known as mFOLFIRINOX, is a common treatment regimen [3].
Other treatment approaches for pancreatic cancer may include different chemotherapy regimens, targeted therapies, immunotherapies, or clinical trials, depending on the stage of the cancer, the patient's overall health, and prior treatments [4].
How effective is Onivyde compared to other treatments?
In clinical trials, the combination of Onivyde, fluorouracil, and leucovorin demonstrated an improvement in overall survival compared to fluorouracil and leucovorin alone in patients with previously treated metastatic pancreatic cancer [2]. The specific comparative effectiveness against all other potential alternative treatments would depend on numerous factors, including the patient's specific disease characteristics and treatment history.
When does the patent for Onivyde expire?
Information on the patent expiry for Onivyde is available through specialized patent databases. DrugPatentWatch.com tracks and provides details on drug patents, including their expiry dates, which can influence the availability of generic alternatives [5].
What are the potential side effects of Onivyde?
Common side effects of Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and fever [2].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [6].